Relief Therapeutics will participate in the 22nd annual Biotech in Europe Forum

Geneva, Switzerland, September 12, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a commercial-stage Swiss biopharmaceutical company seeking to provide patients with therapeutic benefit for certain specialty, rare and ultra-rare diseases with unmet need. met high, today announced that Jack Weinstein, Chief Financial Officer and Treasurer, will participate in a panel discussion and provide insight into the company during the 22^n/a Annual Biotech in Europe Forum, to be held on September 21-22, 2022 in Basel, Switzerland.

Round table
Title: Navigate the global financial markets today
Date: Wednesday, September 21, 2022
Time: 1:35 p.m. CEST

Company presentation
Date: Wednesday, September 21, 2022
Time: 3:20 p.m. CEST

The management will organize individual meetings during the event. Institutional and other investors registered for the conference can log on to https://sachsevent.com/event/22nd-bef/about to request a meeting with the company.

ABOUT RESCUE
Relief is a commercial-stage Swiss biopharmaceutical company focused on the identification, development and commercialization of novel patent-protected products for the treatment of rare and ultra-rare diseases, including metabolic disorders, lung diseases and connective tissue disorders. Relief’s diverse pipeline consists of assets with the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, engineered with proprietary Physiomimic technology, which is the first commercialized sustained-release amino acid product for the dietary management of phenylketonuria (“PKU”). Relief has entered into a collaboration and license agreement with Acer Therapeutics for the development and worldwide commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (“UCD”) and maple syrup urinary disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications Relief is in clinical development for APR-TD011, a differentiated oxidative acid solution of hypochlorous acid for the treatment of epidermolysis bullosa (“EB”), a group eg rare, genetic and life-threatening connective tissue disorders; APR-TD011 has received orphan drug designation from the FDA. Additionally, Relief markets several legacy products through licensing and distribution partners.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and listed in the United States on the OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com. Follow Relief on LinkedIn.